Hearing aid demand grows as Taiwan ages and seniors go digital
DigiMax says stigma and prices near US$2,000 per ear still lead many seniors to delay treatment.
Taiwan’s ageing population is lifting demand for hearing care, but stigma, high prices and limited awareness continue to stop many older adults from seeking help early.
Hope Hung, Sales Manager at DigiMax, said during Medical Taiwan 2026 that more than 20% of Taiwan’s population is now aged 65 or older, whilst around 40% of seniors experience some degree of hearing loss.
The figures point to a growing need for hearing tests and assistive devices, particularly as untreated hearing loss can affect communication, work performance, social participation and quality of life.
“Awareness is increasing around the impact of untreated hearing loss on quality of life, work performance and social engagement,” Hung said.
Demand is also being shaped by changing technology habits among older people. Many seniors in Taiwan already use smartphones and social media services such as Facebook and Line.
“They expect hearing aids to connect seamlessly with their everyday devices,” Hung said.
Access remains a major barrier. Hung said some people still see hearing loss as a sign of ageing or disability and hesitate to seek professional support. Cost can add to the delay, with premium hearing aids priced at about US$2,000 for one ear.
“The biggest challenges are stigma, price and lack of awareness about hearing health,” she said. “There are many people who still don’t know where to get hearing tests and professional assistance.”
Over the next three years, Hung expects improvements in artificial intelligence and device technology to make hearing aids easier to use and more effective for daily communication.
She also expects adoption to rise as the devices become more familiar and less closely associated with disability. Wider take-up, however, will still depend on lower prices, easier access to testing and earlier intervention for people experiencing hearing loss.
Commentary
AI drug discovery, GLP-1, and the next wave of Hong Kong biotech listings
Beyond symptom control: Redefining IMID care in Malaysia
How decentralised clinical trials can unlock Asia's research potential